Literature DB >> 30711487

Complement Factor H Mutation W1206R Causes Retinal Thrombosis and Ischemic Retinopathy in Mice.

Delu Song1, Yoshiyasu Ueda2, Rupak Bhuyan1, Imran Mohammed2, Takashi Miwa2, Damodar Gullipali2, Hangsoo Kim2, Lin Zhou2, Ying Song1, Hannah Schultz1, Albert Bargoud1, Joshua L Dunaief3, Wen-Chao Song4.   

Abstract

Single-nucleotide polymorphisms and rare mutations in factor H (FH; official name, CFH) are associated with age-related macular degeneration and atypical hemolytic uremic syndrome, a form of thrombotic microangiopathy. Mice with the FH W1206R mutation (FHR/R) share features with human atypical hemolytic uremic syndrome. Herein, we report that FHR/R mice exhibited retinal vascular occlusion and ischemia. Retinal fluorescein angiography demonstrated delayed perfusion and vascular leakage in FHR/R mice. Optical coherence tomography imaging of FHR/R mice showed retinal degeneration, edema, and detachment. Histologic analysis of FHR/R mice revealed retinal thinning, vessel occlusion, as well as degeneration of photoreceptors and retinal pigment epithelium. Immunofluorescence showed albumin leakage from blood vessels into the neural retina, and electron microscopy demonstrated vascular endothelial cell irregularity with narrowing of retinal and choroidal vessels. Knockout of C6, a component of the membrane attack complex, prevented the aforementioned retinal phenotype in FHR/R mice, consistent with membrane attack complex-mediated pathogenesis. Pharmacologic blockade of C5 also rescued retinas of FHR/R mice. This FHR/R mouse strain represents a model for retinal vascular occlusive disorders and ischemic retinopathy. The results suggest complement dysregulation can contribute to retinal vascular occlusion and that an anti-C5 antibody might be helpful for C5-mediated thrombotic retinal diseases.
Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30711487      PMCID: PMC6458521          DOI: 10.1016/j.ajpath.2019.01.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Progressive subretinal fibrosis in a child following hemolytic uremic syndrome.

Authors:  R Krott; U Querfeld; K U Bartz-Schmidt; H Hammers; W Hammers; K Heimann
Journal:  Retina       Date:  1999       Impact factor: 4.256

2.  Hemolytic uremic syndrome associated with Purtscher-like retinopathy.

Authors:  A K Lauer; M L Klein; W D Kovarik; E A Palmer
Journal:  Arch Ophthalmol       Date:  1998-08

3.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

4.  Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.

Authors:  Yoshiyasu Ueda; Imran Mohammed; Delu Song; Damodar Gullipalli; Lin Zhou; Sayaka Sato; Yuan Wang; Shuchi Gupta; Zhongjian Cheng; Hong Wang; Jialing Bao; Yingying Mao; Lawrence Brass; X Long Zheng; Takashi Miwa; Matthew Palmer; Joshua Dunaief; Wen-Chao Song
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

5.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.

Authors:  A Richards; M R Buddles; R L Donne; B S Kaplan; E Kirk; M C Venning; C L Tielemans; J A Goodship; T H Goodship
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

6.  Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Daisuke Ito; Hangsoo Kim; Sayaka Sato; Damodar Gullipalli; Lin Zhou; Madhu Golla; Delu Song; Joshua L Dunaief; Matthew B Palmer; Wen-Chao Song
Journal:  Kidney Int       Date:  2019-02-27       Impact factor: 10.612

7.  Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences?

Authors:  Anis Larakeb; Sandrine Leroy; Véronique Frémeaux-Bacchi; Marta Montchilova; Béatrice Pelosse; Olivier Dunand; Georges Deschênes; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2007-07-10       Impact factor: 3.714

8.  Rare Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related Macular Degeneration.

Authors:  Michael P Triebwasser; Elisha D O Roberson; Yi Yu; Elizabeth C Schramm; Erin K Wagner; Soumya Raychaudhuri; Johanna M Seddon; John P Atkinson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

Review 9.  Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy.

Authors:  Lindsay Keir; Richard J M Coward
Journal:  Pediatr Nephrol       Date:  2010-10-15       Impact factor: 3.714

10.  Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome.

Authors:  J E Ramos de Carvalho; R O Schlingemann; M Oranje; F J Bemelman; M J van Schooneveld
Journal:  Int Ophthalmol       Date:  2017-03-08       Impact factor: 2.031

View more
  2 in total

1.  COVID-19, microangiopathy, hemostatic activation, and complement.

Authors:  Wen-Chao Song; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  The complement C3a-C3aR and C5a-C5aR pathways promote viability and inflammation of human retinal pigment epithelium cells by targeting NF-κB signaling.

Authors:  Shasha Luo; Huiyan Xu; Xuechun Gong; Jinyan Shen; Xuan Chen; Zhifeng Wu
Journal:  Exp Ther Med       Date:  2022-06-07       Impact factor: 2.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.